About Vion

Vion Vision

We are committed to extending the lives and improving the quality of life of cancer patients worldwide by bringing innovative cancer treatments to market.

Incorporated in March 1992 to develop cancer therapies, Vion has been a publicly-traded company since 1995. Vion is now traded on the OTC Bulletin Board under the symbol “VION”. Vion has two anticancer compounds in human clinical testing.

Clinical Development

Vion is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. In February 2009, we filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for our potential product, Onrigin™ (laromustine) Injection, formerly Cloretazine® (VNP40101M), for remission induction treatment of acute myeloid leukemia (AML) in elderly de novo poor-risk patients. The Company has announced that the NDA has been accepted for a standard review by the FDA and that the user fee goal date for an FDA decision is December 12, 2009. There can be no assurance that the NDA will be approved by the FDA in 2009, or at all.

In addition, four clinical trials of Onrigin™ are underway in: (i) AML and myelodysplastic syndrome (MDS) in combination with cytarabine; (ii) AML and MDS in combination with standard remission-induction therapy; (iii) AML with unfavorable cytogenetics in combination with standard remission-induction chemothrapy; and (iv) brain tumors in combination with temozolomide.

Our second potential product, Triapine®, is being evaluated in trials sponsored by the National Cancer Institute.